Clinical Trial Update: Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the cardiovascular effects of agomelatine versus escitalopram in adults with major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Agomelatine (agomelatine)
• Escitalopram (escitalopram)

Snippet

Sponsor: Baker Heart and Diabetes Institute | Conditions: Major Depressive Disorder (MDD) | Phase 4 | Status: UNKNOWN